Endocrine Abstracts

Introduction: Megestrol acetate (MA) has been used in various cancers as a palliative agent to treat cancer cachexia. It has glucocorticoid activity and can induce significant secondary adrenal suppression. We designed this study to determine the extent of adrenal insufficiency in cancer patients receiving MA and find out whether ther was any predictive factor for this.Methods: Thirty-one patients (11 females and 20 males, aged 48–83 years) who were...